Altimmune Stock

Altimmune CapEx/D&A

CapEx to Depreciation Ratio of Altimmune (ALT) as of Aug 17, 2026.

CapEx/D&A

0.00

Last updated:

CapEx to Depreciation Ratio of Altimmune is 2026 0.00 . CapEx to Depreciation Ratio of Altimmune was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Altimmune Stock analysis

What does Altimmune do? Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Altimmune stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Altimmune since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Altimmune with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

Cash Flow — Altimmune

All Key Metrics — Altimmune